drugset
drugset / Trial / NCT04154800

A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants

NCT04154800 ↗

Phase 1 Completed 114 enrolled Bristol-Myers Squibb
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the safety and tolerability of BMS-986209 in healthy participants. The first-in-human study is designed in 3 parts that vary based on duration and food effect.

Timeline

Start
2019-12-06
Primary completion
2021-08-31
Completion
2021-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986209 Unknown — —
Background Diltiazem Small molecule — —
Background Itraconazole Small molecule — —

Indications

No indication recorded.